Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis

被引:139
作者
Björnsson, E [1 ]
Boberg, KM
Cullen, S
Fleming, K
Clausen, OP
Fausa, O
Schrumpf, E
Chapman, RW
机构
[1] Sahlgrens Univ Hosp, Dept Internal Med, Sect Gastroenterol & Hepatol, SE-41345 Gothenburg, Sweden
[2] Natl Hosp Norway, Dept Med, Oslo, Norway
[3] Natl Hosp Norway, Inst Pathol, Oslo, Norway
[4] John Radcliffe Hosp, Oxford OX3 9DU, England
关键词
D O I
10.1136/gut.51.5.731
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Patients with cholestatic liver function tests and histological features of primary sclerosing cholangitis (PSC) but a normal cholangiogram are considered to have small duct PSC. The natural history of this condition is unknown. Methods: Thirty three patients with small duct PSC were identified among patients admitted for diagnostic workup of cholestatic liver function tests in one centre in the UK (Oxford) and one centre in Norway (Oslo). A total of 260 patients with large duct PSC were compared, and prognosis in terms of death, cholangiocarcinoma, biochemical features, histological features, and symptoms analysed. Results: Mean age at diagnosis was 38 years and 39 years in small duct and large duct PSC, respectively. Mean follow up was 106 months in small duct and 105 months in large duct patients. Four patients originally considered to have small duct developed large duct PSC. Two of these underwent liver transplantation during follow up. Of the remainder who did not develop large duct PSC, two patients died during follow up: one of liver failure and the other of cardiac death unrelated to her liver disease. A total of 122 (47%) large duct patients either required liver transplantation (34 patients) or died (88 patients). Small duct patients had a significantly better survival compared with large duct patients. Among small duct patients, none developed cholangiocarcinoma compared with 28 of 260 (11%) large duct patients. Conclusions: Patients with small duct PSC seem to have a good prognosis in terms of survival and development of cholangiocarcinoma. Small duct PSC progresses to large duct PSC in a small proportion of patients.
引用
收藏
页码:731 / 735
页数:5
相关论文
共 27 条
[1]  
AADLAND E, 1987, SCAND J GASTROENTERO, V22, P655, DOI 10.3109/00365528709011139
[2]  
ANGULO P, 2000, GASTROENTEROLOGY, V120, pA33
[3]   CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis [J].
Björnsson, E ;
Kilander, A ;
Olsson, R .
LIVER, 1999, 19 (06) :501-508
[4]   HEPATOBILIARY DISEASE IN ULCERATIVE-COLITIS - AN ANALYSIS OF 18 PATIENTS WITH HEPATOBILIARY LESIONS CLASSIFIED AS SMALL-DUCT PRIMARY SCLEROSING CHOLANGITIS [J].
BOBERG, KM ;
SCHRUMPF, E ;
FAUSA, O ;
ELGJO, K ;
KOLMANNSKOG, F ;
HAALAND, T ;
HOLTER, E .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1994, 29 (08) :744-752
[5]   Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis [J].
Broome, U ;
Olsson, R ;
Loof, L ;
Bodemar, G ;
Hultcrantz, R ;
Danielsson, A ;
Prytz, H ;
SandbergGertzen, H ;
Wallerstedt, S ;
Lindberg, G .
GUT, 1996, 38 (04) :610-615
[6]  
Casali AM, 1998, HISTOPATHOLOGY, V32, P449
[7]  
Chapman RW, 2000, FALK SYMP, V114, P279
[8]  
CHAPMAN RW, 1981, DIGEST DIS SCI, V26, P78
[9]  
CHAPMAN RW, 1980, GUT, V21, P1870
[10]  
Chapman RW, 1997, PRIMARY SCLEROSING C, P55